SCHEMBL22494156

SCHEMBL22494156

CC(C)CCN1CCN(C)C(=O)C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.70
▸ SORT1 Q99523 2/20 0.41
▸ GRIA1 P42261 1/20 0.38
▸ GRIA2 P42262 1/20 0.38
▸ GRIA3 P42263 1/20 0.38
▸ GRIA4 P48058 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ BRD4 O60885 1/20 0.34
▸ BRD2 P25440 1/20 0.34
▸ LMNA P02545 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ PTGS1 P23219 1/20 0.34
▸ APEX1 P27695 1/20 0.34
▸ THPO P40225 1/20 0.34
▸ PMP22 Q01453 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16260596 0.82 PIK3CD (1.00) PIK3CDSMN1; SMN2BRD4BRD2LMNA
SCHEMBL4546633 0.81 PIK3CD (0.47) PIK3CDSORT1GRIA1GRIA2GRIA3
SCHEMBL25663983 0.80 PIK3CD (0.58) PIK3CDLMNAMEN1CYP3A4CYP2C9
SCHEMBL6888668 0.78 PIK3CD (0.60) PIK3CDBRD4BRD2MEN1KMT2A
SCHEMBL25023266 0.78 PIK3CD (0.44) PIK3CDSORT1GRIA1GRIA2GRIA3
SCHEMBL18233606 0.77 PIK3CD (0.59) PIK3CDBRD4BRD2
SCHEMBL19158837 0.76 PIK3CD (0.58) PIK3CDBRD4BRD2
SCHEMBL749892 0.76 PIK3CD (0.58) PIK3CDSMN1; SMN2BRD4BRD2LMNA
SCHEMBL18226610 0.76 PIK3CD (0.58) PIK3CDBRD4BRD2KMT2AALDH1A1
SCHEMBL1156274 0.75 PIK3CD (0.62) PIK3CDBRD4BRD2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 — — US disclosed
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-11-17 — — US disclosed
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB PIK3CD 130/4885SORT1 4347/4885GRIA1 4065/4885
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB PIK3CD 119/4885SORT1 4407/4885GRIA1 4034/4885
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB PIK3CD 130/4885SORT1 4347/4885GRIA1 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback